Vor Biopharma, Inc. (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
$15.74
<$0.01(<0.01%)
At close: 4:00 PM EST
$15.74
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)1.07M
Market Cap
$769.10M
Enterprise Value-$285.57M
Total Cash (Recent Filing)$455.21M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)<0.1
Beta4.90
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)52.28
Shares Outstanding48,847,504
10 Day Avg. Volume1,386,708
30 Day Avg. Volume1,068,330
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit336.76
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$37.00Price Target Upside135.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Global Phase 3 ProgressOngoing global Phase 3 enrollment across multiple regions supports potential worldwide registration and demonstrates advancing development momentum for telitacicept.
Mechanism DifferentiationDual BAFF/APRIL inhibition targets IgA and IgM-driven disease biology, offering a potential clinical advantage over therapies that only target IgG or broadly deplete B cells.
Sjögren's Commercial OpportunityLate-stage development in Sjögren's disease targets a large unmet need with no approved disease‑modifying systemic therapy, and convenient at‑home subcutaneous dosing may aid patient adoption.
Bears Say
Concentration And Competitive RiskReliance on a single drug candidate amid intense competition raises the risk that the company may struggle to win market share unless clear differentiation is demonstrated.
Data Translatability RiskClinical results observed in China may not translate to global trials, creating regulatory and commercial uncertainty until a positive global phase 3 readout is confirmed.
Financing And Dilution RiskEquity raises and outstanding warrants increase the prospect of shareholder dilution and have led analysts to revise financing assumptions downward.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $769.10M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is May 07, 2026 which is in 27 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on Mar 30, 2026. The company reported $52.28 earnings per share for the quarter, beating the consensus estimate of $15.675 by $36.605.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 48,847,504 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of $52.28 in its last earnings report, beating expectations of $15.675. Following the earnings report the stock price went up 1.519%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (135.07% Upside)
$37.00 (135.07% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.13%
12-Months-Change
Fundamentals
Return on Equity
72.70%
Trailing 12-Months
Asset Growth
203.89%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$37.00
▲(135.07% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---